Alzamend Neuro, Inc. (ALZN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-17

Key Insights

Alzamend Neuro held its annual shareholder meeting and the stockholders voted on key proposals, including the election of directors and approval of the 2025 Stock Incentive Plan.
The company received shareholder approval to implement a reverse stock split, which could potentially improve stock liquidity and market perception.
Shareholders approved the ratification of the independent registered public accounting firm for the upcoming fiscal year.

Insider Trading Filed: 2026-04-16

Key Insights

Milton C. Ault III, the Executive Chairman of Hyperscale Data, Inc., has increased his beneficial ownership in Alzamend Neuro, Inc. (ALZN) by acquiring 108,388 shares on April 14, 2026.
Ault Lending, LLC, a wholly-owned subsidiary of Hyperscale Data, Inc., holds a significant indirect beneficial ownership stake in Alzamend Neuro, Inc. (ALZN).
Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC, which are affiliated with Milton C. Ault III, also hold small indirect beneficial ownership stakes in Alzamend Neuro, Inc. (ALZN).

Current Report Filed: 2026-03-20

Key Insights

Alzamend Neuro, Inc. (ALZN) received a notice from Nasdaq indicating that the company's stockholders' equity did not meet the minimum $2.5 million requirement for continued listing on the Nasdaq Capital Market.
The company has been given 45 days to submit a plan to regain compliance, and if accepted, may have up to 180 days to evidence compliance.
There is no assurance that the company's plan will be accepted or that it will be able to regain compliance, and failure to do so could result in delisting of the company's common stock.

Quarterly Report Filed: 2026-03-11

Key Insights

The company has reported significant increases in research and development expenses, indicating a focus on advancing its pipeline of Alzheimer's disease and neurodegenerative disorder treatments.
Alzamend Neuro has been actively pursuing various licensing agreements and strategic partnerships, which could potentially expand its product portfolio and commercialization opportunities.
The company's financial position appears strained, with a continued reliance on equity financing and a growing accumulated deficit, which may raise concerns about its long-term sustainability.

Current Report Filed: 2026-03-06

Key Insights

Alzamend Neuro, Inc. has entered into an at-the-market (ATM) equity offering program, allowing them to raise up to $3 million in additional capital to fund their operations.
The ATM offering will be made under Alzamend's existing shelf registration statement, providing flexibility to access the capital markets as needed.
Ascendiant Capital Markets, LLC has been appointed as the sales agent, indicating the company's efforts to secure additional financing to support its business initiatives.

Insider Trading Filed: 2025-12-30

Key Insights

Insider Milton C. Ault III sold 1,851 shares of Alzamend Neuro, Inc. (ALZN) at $2.0665 per share, reducing his direct ownership to 0 shares.
Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC, entities controlled by Milton C. Ault III, continue to hold a total of 19,389 shares of ALZN indirectly.
The insider sale appears to be for the purpose of realizing tax losses, as indicated by the filing.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.